In metastatic non‑small cell lung cancer with leptomeningeal disease, should comprehensive next‑generation sequencing (NGS) and targeted therapy be performed before considering intrathecal chemotherapy?

NGS and Targeted Therapy Should Be Prioritized Over Intrathecal Chemotherapy in EGFR-Mutant NSCLC with Leptomeningeal Disease

In metastatic NSCLC with leptomeningeal metastases (LM), comprehensive NGS testing and high-CNS-penetration targeted therapy should be performed first and serve as the primary treatment strategy, with intrathecal chemotherapy reserved as a supplementary intervention for specific clinical scenarios.

Rationale: The Paradigm Shift in LM Management

The treatment landscape for NSCLC-related LM has fundamentally changed with the emergence of third-generation tyrosine kinase inhibitors (TKIs) that achieve therapeutic CSF concentrations. For patients with actionable driver mutations—particularly EGFR, ALK, RET, ROS1, and other targetable alterations—systemic targeted therapy with CNS-penetrant agents now represents the cornerstone of treatment 1, 2.

Why NGS Testing Must Come First

Perform comprehensive NGS on both cerebrospinal fluid (CSF) and plasma samples at LM diagnosis 2, 3. This dual approach is critical because:

• CSF cfDNA detects mutations in 92.9% of LM cases versus only 64.2% in plasma 3
• CSF testing identifies resistance mechanisms (EGFR amplification, MET amplification, RB1 mutations) that plasma misses entirely 3
• Driver mutation concordance between CSF and primary tumor is 100%, but CSF may reveal additional mutations not detected in archival tissue 4, 5
• Molecular profiling directly determines whether high-efficacy targeted therapy is available—fundamentally altering the treatment algorithm 2, 6

The Evidence for Targeted Therapy as First-Line

For EGFR-mutant NSCLC with LM, the most recent guidelines strongly recommend:

Third-generation EGFR TKIs (osimertinib) as first-line therapy 1, 7. The 2025 Congress of Neurological Surgeons guidelines (Level III evidence) specifically state that "EGFR TKIs be used to increase median survival, specifically the third-generation TKI osimertinib for patients with EGFR-mutant NSCLC" in leptomeningeal disease 1.

For ALK-positive NSCLC with LM: second-generation ALK inhibitors (alectinib) are recommended 1. The 2024 ASCO guidelines reinforce that alectinib or brigatinib should be offered to treatment-naive patients 7.

For other actionable mutations (RET, ROS1, NTRK, MET exon 14, BRAF V600E), mutation-specific targeted agents should be prioritized per the 2024 ASCO Stage IV NSCLC guidelines 8, 7.

When to Consider Intrathecal Chemotherapy

Intrathecal therapy should be positioned as supplementary, not primary treatment 2, 9. Consider IT chemotherapy in these specific scenarios:

1. Patients with wild-type tumors lacking actionable mutations who have exhausted systemic options
2. As adjunct therapy in patients with bulky leptomeningeal disease causing obstructive hydrocephalus or focal neurological deficits requiring rapid local control 2
3. In cases of confirmed resistance to targeted therapy where CSF molecular profiling shows persistent disease despite adequate systemic drug levels 4, 5
4. Patients with thin linear LM deposits and unobstructed CSF flow who may benefit from direct CSF drug delivery 2

The Intrathecal Evidence Base

Traditional IT agents (methotrexate, cytarabine, thiotepa) historically achieved median survival of only 2-4 months 10, 2. More recent studies with intrathecal pemetrexed show improved outcomes:

• Clinical response rate: 64% 4
• Median intracranial PFS: 5.3 months 4
• Median OS: 12.0 months when combined with systemic therapy 4
• In refractory LM treated with IP-based multimodal therapy: median PFS 9.6 months 5

However, these outcomes still occur in the context of concurrent systemic targeted therapy 4, 5, 11. The 2024 Society for Neuro-Oncology/ASCO consensus emphasizes that "systemic therapies with CNS bioactivity and blood-CSF barrier permeability should be prioritized in all patients with LM" 2.

Practical Treatment Algorithm

Step 1: Immediate Diagnostic Workup

• Obtain CSF for cytology (minimum 5-10 mL, processed within 30 minutes) 2
• Perform NGS on CSF cfDNA and plasma simultaneously 2, 3
• MRI brain and spine with contrast 2
• Assess CSF flow with radionuclide study if IT therapy contemplated 10

Step 2: Treatment Selection Based on Molecular Profile

If actionable mutation detected (EGFR, ALK, ROS1, RET, NTRK, MET exon 14, BRAF V600E):

• Initiate high-CNS-penetration targeted therapy immediately 1, 7, 2
• EGFR-mutant: osimertinib 1, 7
• ALK-positive: alectinib or brigatinib 1, 7
• Other mutations: per ASCO driver alteration guidelines 7
• Reserve IT chemotherapy for symptomatic bulky disease or documented targeted therapy resistance 2, 9

If no actionable mutation (wild-type):

• Consider systemic chemotherapy with CNS-active agents (pemetrexed-based) 2
• Evaluate for IT chemotherapy if performance status adequate and CSF flow unobstructed 2
• Consider immunotherapy if PD-L1 ≥50% and stable CNS disease 1

Step 3: Adjunctive Measures

• Ommaya reservoir placement preferred over lumbar punctures if IT therapy planned (lower complication rates 2-10%, superior drug distribution) 10, 2, 12
• Focal radiotherapy for symptomatic bulky deposits or obstructive lesions 2
• VP shunt for symptomatic hydrocephalus as palliative measure 2

Critical Pitfalls to Avoid

1. Do not delay targeted therapy to pursue IT chemotherapy first in mutation-positive patients—this wastes the window of maximal systemic treatment benefit 2, 9, 6

2. Do not rely on plasma NGS alone—CSF testing detects resistance mechanisms and mutations missed by plasma in 28.6% of cases 3

3. Do not administer IT chemotherapy without confirming unobstructed CSF flow—abnormal flow occurs in one-third of LM patients and causes treatment failure and toxicity 10

4. Do not use first- or second-generation EGFR TKIs when third-generation agents are available—osimertinib has superior CSF penetration 1, 13

5. Avoid single-modality IT chemotherapy—historical data show median survival of only 2-4 months without concurrent systemic therapy 10, 2

Quality of Life Considerations

Targeted therapy offers superior quality of life compared to IT chemotherapy because:

• Oral administration versus repeated lumbar punctures or reservoir access
• Lower rates of myelosuppression and neurological toxicity 4
• Addresses both CNS and extracranial disease simultaneously 2
• Avoids surgical risks of Ommaya placement (infection, hemorrhage, malfunction) 2, 12

The 2026 Chinese Expert Consensus explicitly advocates for "high-CNS-penetration targeted therapies as the first-line intervention, while local treatments (such as intrathecal injection and radiotherapy) are positioned as supplementary measures" 9.

The evidence unequivocally supports molecular profiling first, targeted therapy as primary treatment, and selective use of intrathecal chemotherapy as an adjunct—not as initial therapy—in the modern management of NSCLC-related leptomeningeal metastases.